Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-4050 in Cystic Fibrosis Patients with Abnormal Glucose Tolerance
NCT02955888Phase 2Terminated
- Sponsor
- Liminal BioSciences Inc.
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing PBI4050 with Placebo (2 arms). Primary endpoint: Number of Subjects with Adverse Events at 1 year. Started Jan 2017; status: terminated.
02
Drugs
fezagepras
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02955888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955888.